HER2CLIMB-05 Boosts First-Line Maintenance in HER2-Positive Metastatic Breast Cancer
核心洞察
Adding tucatinib to trastuzumab and pertuzumab maintenance after first-line induction chemotherapy extended median investigator-assessed PFS to 24.9 months versus 16.3 months with placebo in the phase III HER2CLIMB-05 trial.
The hazard ratio was 0.641 (95% CI, 0.514-0.799; P<0.0001), an 8.6-month median gain and a 36% relative reduction in progression or death across 654 randomized patients.
PFS benefit was consistent across prespecified subgroups including hormone receptor status, baseline brain metastases (搜索) and induction response, while overall survival and CNS outcomes remain immature.
The phase III HER2CLIMB-05 trial tested a different question in HER2-positive metastatic breast cancer (搜索): rather than altering induction therapy, it intensified maintenance after initial disease control. In the randomized, double-blind international study, adding the HER2 (搜索)-selective tyrosine kinase inhibitor tucatinib to trastuzumab and pertuzumab significantly prolonged progression-free survival compared with the antibody combination alone. Median investigator-assessed PFS was 24.9 months with tucatinib versus 16.3 months with placebo (HR 0.641; 95% CI, 0.514-0.799; P<0.0001), an 8.6-month gain and a 36% relative reduction in the risk of progression or death. Blinded independent central review findings were consistent with the primary analysis.
The trial enrolled 654 patients with centrally confirmed HER2-positive metastatic breast cancer (搜索) and no evidence of progression after four to eight cycles of first-line induction therapy, randomized 1:1 to tucatinib 300 mg twice daily plus trastuzumab and pertuzumab or placebo plus the two antibodies. Benefit was reported across prespecified subgroups, including hormone receptor status (HR approximately 0.55 for HR-negative and 0.73 for HR-positive disease), baseline brain metastases (搜索), previous anti-HER2 (搜索) treatment and best response to induction. Among the roughly 12% of patients per arm with brain metastases at baseline, median CNS-PFS was 8.5 months with tucatinib versus 4.3 months with placebo (HR 0.719; 95% CI, 0.406-1.273), a direction favoring tucatinib but with a confidence interval crossing 1. Overall survival remains immature.
Toxicity was higher with tucatinib. Diarrhea occurred in approximately 67% versus 47% of controls, nausea was more frequent, and ALT and AST elevations reflected the drug's known hepatic profile. Serious treatment-emergent adverse events occurred in 16.9% versus 8.0%, and events leading to discontinuation of any study therapy in 13.8% versus 4.6%. Drug-induced liver injury was reported in about 1.2% of tucatinib patients and none in the control group, including one grade 5 case confounded by concomitant hepatotoxic medications. The study was sponsored by Seagen, subsequently acquired by Pfizer, and the research summary was funded by Pfizer; the summary notes tucatinib plus trastuzumab and pertuzumab was not approved for first-line maintenance in this setting at the time of publication.